Patent protection in India is commonly described as a mechanism to reward innovation although that description is incomplete. The Indian patent system is not designed merely to reward inventors. It is structured to regulate innovation. It grants exclusivity only after subjecting an invention to statutory scrutiny, technical examination and public-interest safeguards.
The framework governing patent protection in India is contained in the Patents Act, 1970, read with the Patents Rules, 2003, as amended from time to time. The statute establishes not only what qualifies as an invention but also what does not. It prescribes procedures for filing, examination, opposition, grant, enforcement and revocation. The system is layered and conditional. So understanding patent protection in India requires moving beyond definitions and examining how the law actually operates.
The Statutory Foundation of an Invention
Section 2(1)(j) of the Patents Act, which defines an invention as a new product or process involving an inventive step and capable of industrial application. Three cumulative requirements must be satisfied:
- Novelty
- Inventive step
- Industrial applicability
Failure in any one element leads to rejection. Even if these elements are satisfied, the invention must not fall within the exclusions listed under Section 3 or the prohibition under Section 4. Hence, patent protection in India is not a matter of registration. It is a matter of qualification.
1. Novelty
The patent law follows a strict novelty standard. Under Sections 29 to 34, an invention is anticipated if it has been publicly disclosed anywhere in the world before the priority date. There is no concept of local novelty. Prior art is global.A single prior disclosure – whether in a patent document, journal article, conference paper or publicly accessible database – can defeat novelty.Examiners frequently rely on prior art references that applicants may not have initially considered. Even close similarities may trigger objections. Novelty analysis requires disciplined prior art search before filing. Post-filing discovery of damaging prior art significantly weakens prosecution strategy. In Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries, Supreme Court observed:
“The fundamental principle of patent law is that a patent is granted only for an invention which must be new and useful. That is to say, it must have novelty and utility. it is essential for the validity of a patent that it must be inventor’s own discovery as opposed to mere verification of what was, already known before the date of the patent.”
2. Inventive Step
Section 2(1)(ja) defines inventive step as a feature involving technical advance as compared to existing knowledge or having economic significance and making the invention not obvious to a person skilled in the art. This provision contains two critical components:
- Technical advance or economic significance
- Non-obviousness
In India, patent examination usually follows a structured method similar to international standards, but it strictly follows the wording of the law. The main question is whether the invention would have been obvious to a skilled person based on existing knowledge. Small improvements, optimizations or combinations of known things often receive objections. The arguments should focus on technical difference, not just commercial benefit. The Patent Office carefully checks the technical contribution. Objections related to inventive step are usually the biggest challenge during patent prosecution.
3. Industrial Applicability
Industrial applicability under Section 2(1)(ac) requires that the invention be capable of being made or used in an industry. The term “industry” is interpreted broadly and encompasses any useful, practical activity – it is not confined to manufacturing in the conventional sense. Agriculture, medicine, communications and software all fall within its scope provided the invention has demonstrable utility in one of them. The requirement eliminates two categories of subject matter. First, purely theoretical or speculative disclosures – an invention that exists only as an abstract possibility without any demonstrated or reasonably predictable practical use will not satisfy this criterion. Second, inventions contrary to well-established natural laws – a perpetual motion machine, for instance, fails industrial applicability because its claimed function is scientifically impossible.
In practice, objections on this ground arise less frequently than novelty or inventive step objections. However, they become particularly relevant in biotechnology and pharmaceutical applications where the utility of a claimed compound may not yet be established at the filing date, and in computer-implemented invention claims where the practical application is unclear from the specification. Applicants must therefore ensure the specification includes a clear, concrete statement of industrial application linked directly to the claimed invention – not merely an assertion that the invention is “useful.”
Section 3 of the Patent Act, 1970
Section 3 lists subject matter that is not considered an invention for the purposes of the Act. These exclusions reflect deliberate legislative policy choices.
Among the significant exclusions:
- Mere discovery of scientific principles
- Mathematical methods
- Business methods
- Computer programs per se
- Mere arrangement or duplication of known devices
- New forms of known substances without enhanced efficacy
- Traditional knowledge
Section 3(d) and Pharmaceutical Patents
Section 3(d) is the most internationally significant provision in Indian patent law and the most directly consequential for pharmaceutical applicants. It excludes from patentability the mere discovery of a new form of a known substance – including salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations and other derivatives – unless such new form results in a significant enhancement of the known efficacy of that substance. The provision is aimed squarely at the pharmaceutical practice of evergreening – the successive patenting of minor modifications to existing drugs in order to extend effective market exclusivity beyond the original patent term. By requiring not merely novelty but enhanced efficacy as a condition of patentability, Section 3(d) sets a higher threshold than Article 27 of TRIPS demands, but one that India has consistently maintained is within its permitted policy space as a WTO member.
The Supreme Court’s landmark decision in Novartis AG v. Union of India (2013) settled the interpretation of Section 3(d) definitively. Novartis sought a patent for the beta crystalline form of imatinib mesylate – the active ingredient in Gleevec, a breakthrough cancer drug. The Court rejected the application, holding that improved bioavailability does not automatically constitute enhanced therapeutic efficacy. The two concepts are legally distinct. A new form that reaches systemic circulation more efficiently does not thereby treat disease more effectively. Only evidence of enhanced therapeutic efficacy – demonstrable improvement in the treatment of the condition for which the drug is indicated – can satisfy Section 3(d). The practical implication for pharmaceutical applicants is that efficacy data must be generated and placed on record. Clinical or pre-clinical studies establishing superior performance over the known substance are essential. Claims unsupported by such data, however strong the chemical novelty, will fail Section 3(d) scrutiny.
Section 3(k) and Software
Section 3(k) excludes mathematical methods, business methods, computer programmes per se and algorithms from patentability. The critical qualifier is “per se” – Parliament did not exclude computer programmes absolutely but only when claimed in their bare, abstract form, divorced from any technical application or effect.
The Indian Patent Office’s Guidelines for Examination of Computer Related Inventions, last updated in 2017, operationalise this distinction through what is commonly called the technical effect test. An examiner assesses the actual contribution of the claimed invention. If that contribution lies solely within the excluded categories, the application fails. If the contribution extends beyond those categories to produce a technical effect – faster processing, reduced memory usage, improved signal transmission, enhanced system security – the application may proceed. The consequence for applicants is largely a drafting question. Claims framed as pure algorithms or software processes will fail. Claims that situate the software within a defined technical system, identify a specific technical problem and claim a measurable technical result stand a substantially better chance. This is consistent with the approach taken in Ferid Allani v. Union of India (Delhi High Court, 2019), where the Court emphasised that the exclusion in Section 3(k) must not be read so broadly as to exclude all computer-implemented inventions – only those that are nothing more than abstract software without technical character.
Filing and Prosecution Process
Patent protection begins with filing under Section 6. Applications may be filed by the true and first inventor, assignee or legal representative. A provisional or complete specification must accompany the application. Section 10 prescribes requirements for specification, including full and particular description and disclosure of the best method known to the applicant.
Publication
Under Section 11A, applications are published after eighteen months from the filing date unless early publication is requested. Publication confers provisional rights to claim reasonable royalty upon eventual grant, but enforcement remains conditional on grant.
Request for Examination
Section 11B requires filing a request for examination within the prescribed time. Failure to do so results in deemed withdrawal. This is a strict procedural requirement. The Patent Office does not automatically examine applications.
Examination and Objections
The Controller examines whether the invention satisfies statutory requirements. Objections are communicated through a First Examination Report.Applicants must respond within prescribed timelines. Amendments are permitted under Section 59, provided they do not broaden the scope beyond original disclosure.Prosecution is often iterative. Claims are refined. Arguments are structured. Technical distinctions are clarified.Grant follows only after compliance.
Opposition Mechanisms
Indian patent law provides both pre-grant and post-grant opposition mechanisms under Section 25. Pre-grant opposition may be filed by any person after publication but before grant. Post-grant opposition may be filed within one year of publication of grant.Grounds include lack of novelty, obviousness, non-patentable subject matter, insufficient disclosure and wrongful obtaining. These mechanisms introduce adversarial scrutiny into the process.
Rights Conferred upon Grant
Section 48 confers exclusive rights on the patentee. In case of product patents, the patentee has the exclusive right to prevent others from making, using, selling, offering for sale or importing the product. In case of process patents, the patentee has the right to prevent use of the process and sale or import of products directly obtained by that process. These rights are territorial and limited to India.
Term and Maintenance
Under Section 53, the term of a patent is twenty years from the date of filing. Annual renewal fees must be paid to maintain the patent. Failure to pay results in lapse, though restoration may be sought under prescribed conditions. Patent protection is not perpetual. It is time-bound and conditional on maintenance.
Working of Patents and Public Accountability
Section 83 of the Patents Act articulates the general principles that govern patent working. Patents are not to be worked in a manner contrary to public health or that prevents reasonable exploitation of natural resources. More specifically, Section 83(f) mandates that the patent is worked in India on a commercial scale to the fullest extent reasonably practicable. This provision reflects the Indian legislative philosophy that a patent is a social bargain – exclusivity is granted in exchange not only for disclosure but for genuine exploitation of the invention within the country. Section 146 requires every patentee and every licensee to furnish statements of working to the Controller. Form 27 must be filed annually by patentees and licensees, detailing the extent to which the patented invention has been worked in India, the value of the product manufactured or imported, and whether the public requirement has been met. Failure to file, or filing of false statements, carries significant consequences.
The practical and strategic importance of Form 27 cannot be understated. In a compulsory licensing proceeding under Section 84, non-working or inadequate working is a primary ground. A patentee who has consistently disclosed on Form 27 that the invention is not being worked in India, or is being satisfied exclusively through imports, has materially weakened their position against any compulsory licence application. This was evident in Natco Pharma v. Bayer Corporation (2012), where the Controller found that Nexavar was not being worked in India to a sufficient extent and that Bayer’s reliance on imported product did not satisfy the working requirement.
Compulsory Licensing
Section 84 permits compulsory licensing after three years from grant if:
- Reasonable requirements of the public are not satisfied
- The patented invention is not available at reasonably affordable price
- The invention is not worked in India
Compulsory licensing underscores the balance between private rights and public interest. Patent protection in India operates within this framework of accountability.
Enforcement and Infringement
Patent infringement arises when exclusive rights under Section 48 are exercised without authorization. Section 108 provides civil remedies, including injunction and damages. In process patents, Section 104A shifts burden of proof to the defendant under specified circumstances. Patent enforcement proceedings often fall under Commercial Courts, which apply expedited procedures.
Revocation and Continuing Scrutiny
Section 64 provides grounds for revocation, including:
- Lack of novelty
- Obviousness
- Non-patentable subject matter
- Insufficient disclosure
- Non-compliance with Section 8
A granted patent remains vulnerable to challenge. The system recognises that grant is not conclusive proof of validity.
Disclosure for Monopoly
Patent protection rests on a disclosure for exclusivity exchange.The inventor receives exclusive rights for a limited period. In return, the invention is disclosed to the public in sufficient detail to enable replication.After expiry of the term, the invention enters the public domain.This mechanism promotes technological dissemination while incentivizing innovation. The Indian patent regime is neither excessively permissive nor hostile to innovation. It is calibrated. Sections 3, 84, 100 and 146 reflect public-interest safeguards. At the same time, Sections 48 and 108 provide strong enforceable rights for valid patents. Patent protection in India is best understood not as an automatic reward but as a regulated privilege conditioned on technical merit and statutory compliance.
Conclusion
The Patents Act, 1970 does not merely create a registration system for inventions – it administers a conditional privilege. Exclusivity is earned through technical merit, disclosed through enabling specification, and maintained through compliance with working, opposition and renewal requirements. At every stage, from Section 2’s definitions to Section 64’s revocation grounds, the statute reserves the right to withdraw or circumscribe what it grants.
What distinguishes India’s patent system from many comparable jurisdictions is its explicit calibration of private rights against public interest. Section 3(d) prevents trivial pharmaceutical patents. Section 84 enables compulsory licensing where public access demands it. Section 146 ensures patents do not become idle monopolies. These provisions are not anomalies – they are the architecture of a system designed for a country where access to technology and medicine carries stakes that raw innovation theory cannot address alone.
For practitioners, the lesson is one of strategy over optimism. A patent application in India must be built on sound prior art analysis, drafted with technical precision, argued through examination with substantive engagement, and maintained with procedural diligence. A patent that survives this process is genuinely strong. One that does not was never entitled to the exclusivity it sought.
References
The Patents Act, 1970 https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_113_1_The_Patents_Act__1970___incorporating_all_amendments_till_1-08-2024.pdf
The Patents (Amendment) Act, 2002 https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_125_1_THE_GAZETTE_OF_INDIA.pdf
TRIPS Agreement (WTO Official ) https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
National IPR Policy, 2016 (Government of India) https://dpiit.gov.in/sites/default/files/National_IPR_Policy_English.pdf
Supreme Court – Novartis AG v. Union of India (Judgment) https://indiankanoon.org/doc/165776436/
Compulsory Licence Order (Bayer Case – 2012) https://indiankanoon.org/doc/28519340/
Compulsory Licensing Copyright Act Copyright Act 1957 Copyright Enforcement Copyright Infringement Copyright Law Copyright Licensing Copyright Registration Copyright Rules CRI Guidelines Deceptive Similarity Goodwill Indian IP Framework Indian Patent Act Indian Patent Law Indian Trademark Law Intellectual Property Law Interim Injunction Inventive Step IP Law India Passing Off Patent Claims Patent Enforcement Patent Examination Patent Infringement Patent law Patent Revocation Patent Rule Pharmaceutical Patents Section 3 Section 11 Section 29 The Patent Act 1970 Trademark Dilution Trademark Enforcement Trademark Infringement Trademark Litigation Trademark Registration Trade Marks Act 1999 Trade Marks Rules 2017 TRIPS Agreement TRIPS Compliance Well-Known Trademark